Abstract
Cell motility is a central feature of a range of normal and pathological processes, including embryonic development, tissue repair, immune cell function, angiogenesis, and cancer metastasis. The dynamics of the actin cytoskeleton power cell migration. A large number of proteins are known or suspected to play roles in regulating actin dynamics. While there are now many available small molecules that target the actin cytoskeleton directly, there is a paucity of specific inhibitors of actin-binding proteins and other immediate regulators of actin dynamics and cell movement. This makes the field of exceptional interest as a meeting place between the goals of chemical biology and the needs of cell biology. Furthermore, while regulators of the cell cycle have been recognized for some time as targets for anti-cancer drug development, controlling actin dynamics and cell motility as a therapeutic approach has received scant attention in comparison until recently. This review deals with small-molecule inhibitors of actin dynamics as they relate to cell shape change and motility, from compounds targeting actin directly to those targeting proteins involved in the fundamental control of the actin cytoskeleton.
Keywords: cell motility, cytoskeleton, actin dynamics, regulation, small molecule, chemical, inhibitors
Current Topics in Medicinal Chemistry
Title: Small-Molecule Inhibitors of Actin Dynamics and Cell Motility
Volume: 3 Issue: 6
Author(s): Gabriel Fenteany and Shoutian Zhu
Affiliation:
Keywords: cell motility, cytoskeleton, actin dynamics, regulation, small molecule, chemical, inhibitors
Abstract: Cell motility is a central feature of a range of normal and pathological processes, including embryonic development, tissue repair, immune cell function, angiogenesis, and cancer metastasis. The dynamics of the actin cytoskeleton power cell migration. A large number of proteins are known or suspected to play roles in regulating actin dynamics. While there are now many available small molecules that target the actin cytoskeleton directly, there is a paucity of specific inhibitors of actin-binding proteins and other immediate regulators of actin dynamics and cell movement. This makes the field of exceptional interest as a meeting place between the goals of chemical biology and the needs of cell biology. Furthermore, while regulators of the cell cycle have been recognized for some time as targets for anti-cancer drug development, controlling actin dynamics and cell motility as a therapeutic approach has received scant attention in comparison until recently. This review deals with small-molecule inhibitors of actin dynamics as they relate to cell shape change and motility, from compounds targeting actin directly to those targeting proteins involved in the fundamental control of the actin cytoskeleton.
Export Options
About this article
Cite this article as:
Fenteany Gabriel and Zhu Shoutian, Small-Molecule Inhibitors of Actin Dynamics and Cell Motility, Current Topics in Medicinal Chemistry 2003; 3 (6) . https://dx.doi.org/10.2174/1568026033452348
DOI https://dx.doi.org/10.2174/1568026033452348 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pretreatment Serum Fibrinogen Levels are Associated with Postoperative Distant Metastasis and Prognosis of Resected Lung Cancer Patient: A Retrospective Study
Current Signal Transduction Therapy Application of PET to the Diagnosis, Staging, and Treatment of Locally Advanced Non-small Cell Lung Cancer
Current Medical Imaging Recent Developments of Flavonoids with Various Activities
Current Topics in Medicinal Chemistry Chronic Granulomatous Disease in Childhood
Current Pediatric Reviews A Review of Preclinical Experiments Toward Targeting M2 Macrophages in Prostate Cancer
Current Drug Targets Population Based Helicobacter pylori Screening and Eradication: Advances Versus Side Effects
Current Pharmaceutical Design Lipids as a Target for Drugs Modulating Multidrug Resistance of Cancer Cells
Current Drug Targets Recent Advances in Characterizing Natural Products that Regulate Autophagy
Anti-Cancer Agents in Medicinal Chemistry Kruppel-Like Factors 4 and 5: Unity in Diversity
Current Genomics miRNAs in Cancer Prevention and Treatment and as Molecular Targets for Natural Product Anticancer Agents
Current Cancer Drug Targets Small Molecules in Cancer Therapy: Cytotoxics and Molecularly Targeted Agents
Current Signal Transduction Therapy Membrane Transporters as Determinants of the Pharmacology of Platinum Anticancer Drugs
Current Cancer Drug Targets MMPs in Ovarian Cancer as Therapeutic Targets
Anti-Cancer Agents in Medicinal Chemistry Anti-diabetic Drug Metformin: Challenges and Perspectives for Cancer Therapy
Current Cancer Drug Targets The Potential of Tetrandrine Against Gliomas
Anti-Cancer Agents in Medicinal Chemistry Molecular Targets for Nutritional Preemption of Cancer
Current Cancer Drug Targets Targeting Tumor Lymphangiogenesis: An Update
Current Medicinal Chemistry Proteomic Approaches for the Study of Transgelins as Tumor-associated Proteins and Potential Biomarkers
Current Proteomics Choline Nutrition Programs Brain Development Via DNA and Histone Methylation
Central Nervous System Agents in Medicinal Chemistry Transcriptional and Post-Transcriptional Regulations of Junction Proteins in Mammalian estes – Implications on Male Contraceptive Development
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)